Novartis Drug Fabhalta Slows Kidney Decline by Nearly Half in Phase III Study
Basel, Switzerland — Novartis announced positive two-year results from its Phase III APPLAUSE-IgAN study, demonstrating that its oral treatment Fabhalta significantly slowed kidney function decline by nearly 50% in adults…